Compare ENTX & OCCI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ENTX | OCCI |
|---|---|---|
| Founded | 2010 | N/A |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Trusts Except Educational Religious and Charitable |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 142.0M | 139.4M |
| IPO Year | 2018 | N/A |
| Metric | ENTX | OCCI |
|---|---|---|
| Price | $2.16 | $5.03 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $10.00 | N/A |
| AVG Volume (30 Days) | 82.8K | ★ 115.8K |
| Earning Date | 11-14-2025 | 12-11-2023 |
| Dividend Yield | N/A | ★ 24.32% |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $124,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $10.19 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 25.25 | N/A |
| 52 Week Low | $1.50 | $5.47 |
| 52 Week High | $3.22 | $10.15 |
| Indicator | ENTX | OCCI |
|---|---|---|
| Relative Strength Index (RSI) | 36.71 | 56.49 |
| Support Level | $2.05 | $4.31 |
| Resistance Level | $2.53 | $5.04 |
| Average True Range (ATR) | 0.22 | 0.16 |
| MACD | -0.07 | 0.07 |
| Stochastic Oscillator | 13.42 | 85.71 |
Entera Bio Ltd is a clinical-stage biopharmaceutical company engaged in the development of orally delivered macromolecule therapeutics, including peptides and therapeutic proteins. The company focuses on underserved, chronic medical conditions where oral administration of a mini tablet peptide or peptide replacement therapy has the potential to significantly shift a treatment paradigm. Its product candidates are; EB613 for the treatment of osteoporosis and EB612 for the treatment of hypoparathyroidism are first-in-class mini tablet formulations of synthetic human PTH (1-34) (teriparatide), designed to have differing pharmacokinetic, or PK, profiles.
OFS Credit Co Inc is a non-diversified, closed-end management investment company. Its investment objective is to generate current income, with a secondary objective to generate capital appreciation through investment in collateralized loan obligation (CLO) equity and debt securities. The company invests in floating rate credit instruments and other structured credit investments, including; collateralized loan obligation (CLO) debt and subordinated (i.e., residual or equity) securities; traditional corporate credit investments, including leveraged loans and high yield bonds; opportunistic credit investments, including stressed and distressed credit situations and long/short credit investments; and other credit-related instruments.